Table 2.
Farooqi et al.
(n = 45) |
Capone et al.
(n = 50) |
Barris et al.
(n = 16) |
Penner et al.
(n = 46) |
Matsubara et al.
(n = 60) |
|
---|---|---|---|---|---|
Follow up (months) | 5.8 (IQR 1.3–6.7) | 6–8 | 7 (IQR 6.0–8.4) | 6 | 3–6 |
Cardiovascular | |||||
Any echo abnormality (at least mild) | |||||
Admission | 80 | 66 | NA | 33 | NA |
Short Term | 18 | 21 | NA | NA | NA |
Mid Term | 8 | 4 | NA | 4 | |
Tricuspid Valve regurgitation | 27 | NA | NA | ||
Admission | 60 | NA | |||
Short Term | 15 | NA | |||
Mid Term | 4 | NA | |||
Mitral valve regurgitation | |||||
Admission | 36 | NA | NA | NA | |
Short Term | 78 | NA | |||
Mid Term | 4 | NA | |||
Left ventricular systolic dysfunction | |||||
Admission | 49 | 52 | 44 | NA | NA |
Short term | 10 | 2 | 13 | NA | |
Mid term | 4 | 0 | 0 | 0 | NA |
Coronary artery dilation or aneurysm | |||||
Admission | 16 | 24 | 19 | 7 | |
Short term | 0 | 2 | 6 | 4 | 2 |
Mid term | 0 | 0 | 6 | 4 | 0 |
Pericardial effusion | |||||
Admission | 44 | NA | NA | 2 | |
Short term | 10 | NA | NA | 2 | |
Mid term | 0 | NA | NA | 2 | |
CMR performed | NA | 22 | 56 | NA | 23 |
Timing of MRI (post-admission) | NA | 2–4 weeks | 9.4 (Range: 8.8–10.0) months | NA | 5 days−9.5 months |
Myocardial edema | NA | 0 | 44 | NA | 21 |
Fibrosis | NA | 0 | 0 | NA | 14 |
6-min walk exercise test (abnormal) | |||||
6 weeks | NA | NA | NA | 65 | NA |
6 month | NA | NA | NA | 45 | NA |
Gastrointestinal | |||||
Symptoms | |||||
Admission | NA | NA | NA | 98 | NA |
Mid term | NA | NA | NA | 13 | NA |
Significant imaging findings | NA | NA | NA | 33 | NA |
Labs (weeks to normalization post-discharge) | |||||
Troponin | 1–4 | 2 | NA | 6 | NA |
BNP | 1–4 | 2 | NA | 6 | NA |
Platelets | 0 | 8 | NA | 6 | NA |
CRP | 1–4 | 2 | NA | 6 | NA |
NA, not available.
Numbers represent % of sample unless otherwise stated. Continuous variables are reported as median (IQR or Range) or mean ± standard deviation. Categorical variables are reported as percent of study sample.